Elevated nocturnal profiles of serum leptin in patients with depression.
Leptin, the protein product of the obese (ob) gene, has been suggested to play a role in the regulation of food intake. As depressive episodes are frequently characterized by loss of appetite, reduced food intake and weight loss, altered leptin secretion might also be expected in patients with depression. Therefore, we examined nocturnal (10.00 p.m. to 7.00 a.m.) secretion of leptin, cortisol, ACTH and growth hormone (GH) in a group of 15 patients with depression and age- and sex-matched controls (age range 23-71 years). In addition, the effects of pulsatile administration of growth hormone-releasing hormone (GHRH), thought to be an endogenous antagonist of corticotropin-releasing hormone (CRH), which in turn is believed to play a critical role for the pathophysiology of depression, on nocturnal hormone secretion were assessed. Patients with depression showed a trend towards elevated nocturnal cortisol secretion (F = 3.8, p < 0.05). Nocturnal serum leptin was significantly higher in patients, despite a reported weight loss (F = 8, p < 0.05), but showed the same sexual dimorphism as in controls (F = 20.9, p < 0.01). No significant differences were seen between patients and controls with regard to plasma GH and ACTH. GHRH treatment increased GH secretion in both patients and controls, while the other hormones were not affected. Furthermore, serum leptin was correlated with body mass index (BMI) in controls, but not in patients with depression, supporting an altered regulation of leptin secretion in depressive illness. Finally, we provide some evidence that in young female patients the normal nocturnal leptin surge is blunted. As glucocorticoids can prevent the fasting-induced decline in serum leptin, we propose that hypercortisolism in depression might counteract the reduction in leptin secretion caused by decreased food intake and weight loss. Elevated serum leptin in depression might in turn further promote CRH release, as shown in animals and, hence, contribute to HPA system hyperactivity seen in depression.
Antonijevic
I A
IA
Department of Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany. irina@mpipsykl.mpg.de
Murck
H
H
Frieboes
R M
RM
Horn
R
R
Brabant
G
G
Steiger
A
A
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000368:Aged; D015992:Body Mass Index; D016009:Chi-Square Distribution; D002940:Circadian Rhythm / Q000502:physiology*; D003863:Depression / Q000097:blood*; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D020738:Leptin; D008297:Male; D008875:Middle Aged; D010901:Pituitary Function Tests / Q000379:methods; D010913:Pituitary-Adrenal System / Q000503:physiopathology*; D011506:Proteins / Q000032:analysis*; D012737:Sex Factors
D020738:Leptin; D011506:Proteins; D019382:Human Growth Hormone; D000324:Adrenocorticotropic Hormone; D013007:Growth Hormone-Releasing Hormone; D006854:Hydrocortisone